With gender inequality a continued area of focus for corporations and workplaces around the globe, the Healthcare Businesswomen’s Association (HBA) recognized Merck & Co. Inc. and Otsuka America Pharmaceutical Inc. for exemplary workplace initiatives working to close the gender gap in the healthcare and life science industries.
A group of scientists from the Nuffield Department of Women’s & Reproductive Health at Oxford University may have found a potential key to finally treating endometriosis, a disease that affects around 176 million women worldwide.
The Healthcare Businesswomen’s Association Board of Directors announced the appointment of Susan O’Connor as Chief Executive Officer of the global not-for-profit association, ushering in a new chapter in the HBA’s mission of advancing women in healthcare.
In a move to help underserved women join the workforce and to strengthen the impact of its employee volunteer efforts, The Bloc joined the business community of Working for Women (W4W).
Pfizer Inc. and BioNTech SE started an international study with 4,000 volunteers to evaluate the safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.
Findings from a Phase III long-term extension study show a once-daily therapy consisting of relugolix with estradiol and norethindrone acetate leads to clinically meaningful reductions in menstrual pain and non-menstrual pelvic pain over one year in women with endometriosis.
Vaccinating nine in 10 girls under the age of 15 years against cervical cancer, and improved screening and treatment of women could reduce infections by 40% and save 5 million lives by 2050, the World Health Organization (WHO) said.
ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of data from the HIV Prevention Trials Network 084 trial of the investigational, long-acting injectable cabotegravir for HIV prevention in women.
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV acquisition in women Findings follow data from HPTN 083, a partner HIV prevention […]
The Healthcare Technology Report announced the Top 25 Women Leaders in Biotechnology of 2020.